Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
molecular glue
Biotech
Kymera suffers Sanofi setback but secures $750M Gilead deal
Sanofi is pulling back from its lead IRAK4 degrader, switching to a preclinical prospect, while Gilead has inked an oncology deal with Kymera.
Nick Paul Taylor
Jun 25, 2025 9:31am
Plexium cuts staff, realigns resources to support pipeline
Jun 3, 2025 4:12pm
Genentech sticks 2nd molecular glue deal with Orionis worth $2B
May 21, 2025 8:30am
Revised Blueprint-VantAI deal turns focus to molecular glues
May 20, 2025 10:32am
Monte Rosa's broad molecular glue degrader plan comes unstuck
Mar 20, 2025 10:07am
AbbVie crafts $1.6B deal with molecular glue biotech Neomorph
Jan 23, 2025 9:58am
